ALYMSYS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ALYMSYS (ALYMSYS).

How it works

Vascular endothelial growth factor (VEGF) inhibitor; binds to VEGF-A and prevents interaction with VEGFR-1 and VEGFR-2, reducing angiogenesis and tumor growth.

What the body does with it

Metabolism	Primarily metabolized by proteolytic catabolism, not hepatic CYP450 enzymes.
Excretion	Primarily hepatic metabolism; <5% excreted unchanged in urine; biliary/fecal excretion of metabolites accounts for >95% of elimination.
Half-life	Approximately 18-32 days (terminal half-life), reflecting slow clearance typical of monoclonal antibodies; supports every-3-week dosing interval.
Protein binding	Mainly bound to albumin and IgG receptors; total plasma protein binding approximately 100% (as a monoclonal antibody, no specific binding proteins); free fraction <0.1%.
Volume of Distribution	Vd approximately 3.7 L (0.05 L/kg), indicating primarily confined to intravascular space; limited extravascular distribution typical of large proteins.
Bioavailability	Intravitreal: 100% (administered directly into vitreous humor); intravenous: negligible bioavailability due to rapid degradation; no oral bioavailability.
Onset of Action	Intravenous: Therapeutic effect typically observed after 4-8 weeks, with maximal response by 12-24 weeks in neovascular age-related macular degeneration.
Duration of Action	Duration of clinical effect persists for approximately 4-6 weeks; requires repeated intravitreal injections every 4 weeks (monthly) to maintain efficacy.

Classification & Brands

Dosing & administration

Bevacizumab 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks in combination with chemotherapy.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; monitor for proteinuria and hypertension. For severe proteinuria (≥2 g/24h), hold dose until resolution.
Liver impairment	No formal studies in hepatic impairment; use caution in patients with severe hepatic impairment (Child-Pugh C). No dose adjustment recommended for mild to moderate impairment.
Pediatric use	Not approved for pediatric use; safety and efficacy not established.
Geriatric use	No specific dose adjustment required; increased incidence of adverse events such as hypertension and arterial thromboembolic events in patients ≥65 years, monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ALYMSYS (ALYMSYS).

Breastfeeding

No data on bevacizumab-awwb in human milk; maternal IgG is excreted, and large protein drugs may be minimally absorbed. M/P ratio unknown. Because of potential for adverse effects in nursing infant, breastfeeding is not recommended during therapy and for at least 6 months after last dose.

Teratogenic Risk

ALYMSYS (bevacizumab-awwb) is a vascular endothelial growth factor (VEGF) inhibitor. Animal studies show teratogenicity including skeletal malformations and embryotoxicity. In humans, VEGF inhibition may impair fetal angiogenesis. First trimester exposure carries risk of major congenital anomalies; second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and intrauterine growth restriction. Contraindicated in pregnancy unless no alternative.

Warnings & precautions

■ FDA Black Box Warning

Gastrointestinal perforations, surgery and wound healing complications, and hemorrhage (including hemoptysis, GI bleeding, and intracranial hemorrhage).

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to bevacizumab or any excipients; recent hemoptysis (≥2.5 mL red blood); untreated CNS metastases (due to bleeding risk); major surgery within 28 days.

Clinical Precautions

Precautions	Gastrointestinal perforations, wound healing complications (discontinue at least 28 days before elective surgery), hemorrhage (discontinue if severe), arterial thromboembolic events (including MI and stroke), hypertension, posterior reversible encephalopathy syndrome (PRES), proteinuria/nephrotic syndrome, ovarian failure, and infusion reactions.
Food/Dietary	No specific food interactions known. Maintain adequate hydration. Avoid grapefruit or grapefruit juice only if specifically instructed by physician.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ALYMSYS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ALYMSYS (ALYMSYS).

How it works

Vascular endothelial growth factor (VEGF) inhibitor; binds to VEGF-A and prevents interaction with VEGFR-1 and VEGFR-2, reducing angiogenesis and tumor growth.

What the body does with it

Metabolism	Primarily metabolized by proteolytic catabolism, not hepatic CYP450 enzymes.
Excretion	Primarily hepatic metabolism; <5% excreted unchanged in urine; biliary/fecal excretion of metabolites accounts for >95% of elimination.
Half-life	Approximately 18-32 days (terminal half-life), reflecting slow clearance typical of monoclonal antibodies; supports every-3-week dosing interval.
Protein binding	Mainly bound to albumin and IgG receptors; total plasma protein binding approximately 100% (as a monoclonal antibody, no specific binding proteins); free fraction <0.1%.
Volume of Distribution	Vd approximately 3.7 L (0.05 L/kg), indicating primarily confined to intravascular space; limited extravascular distribution typical of large proteins.
Bioavailability	Intravitreal: 100% (administered directly into vitreous humor); intravenous: negligible bioavailability due to rapid degradation; no oral bioavailability.
Onset of Action	Intravenous: Therapeutic effect typically observed after 4-8 weeks, with maximal response by 12-24 weeks in neovascular age-related macular degeneration.
Duration of Action	Duration of clinical effect persists for approximately 4-6 weeks; requires repeated intravitreal injections every 4 weeks (monthly) to maintain efficacy.

Classification & Brands

Dosing & administration

Bevacizumab 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks in combination with chemotherapy.

Dosage form	INJECTABLE
Renal impairment	No specific dose adjustment required for renal impairment; monitor for proteinuria and hypertension. For severe proteinuria (≥2 g/24h), hold dose until resolution.
Liver impairment	No formal studies in hepatic impairment; use caution in patients with severe hepatic impairment (Child-Pugh C). No dose adjustment recommended for mild to moderate impairment.
Pediatric use	Not approved for pediatric use; safety and efficacy not established.
Geriatric use	No specific dose adjustment required; increased incidence of adverse events such as hypertension and arterial thromboembolic events in patients ≥65 years, monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ALYMSYS (ALYMSYS).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

Gastrointestinal perforations, surgery and wound healing complications, and hemorrhage (including hemoptysis, GI bleeding, and intracranial hemorrhage).

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to bevacizumab or any excipients; recent hemoptysis (≥2.5 mL red blood); untreated CNS metastases (due to bleeding risk); major surgery within 28 days.

Clinical Precautions

Precautions	Gastrointestinal perforations, wound healing complications (discontinue at least 28 days before elective surgery), hemorrhage (discontinue if severe), arterial thromboembolic events (including MI and stroke), hypertension, posterior reversible encephalopathy syndrome (PRES), proteinuria/nephrotic syndrome, ovarian failure, and infusion reactions.
Food/Dietary	No specific food interactions known. Maintain adequate hydration. Avoid grapefruit or grapefruit juice only if specifically instructed by physician.

Clinical Tips & Counseling

Drug interactions

Loading safety data…